Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Crossover Trial Comparing the Safety and Efficacy of Insulin Lispro With the Safety and Efficacy of Insulin Aspart in Subjects With Type 2 Diabetes on CSII Therapy

NCT01474538 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT01474538
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01474538 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Crossover Trial Comparing the Safety and Efficacy of Insulin Lispro With the Safety and Efficacy of Insulin Aspart in Subjects With Type 2 Diabetes on CSII Therapy
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2011
Completion date
February 28, 2013
Enrollment
122 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes mellitus